Matthias Eiber

List of Publications by Year
in descending order

60 papers	6,639 citations	101543 36 h-index	123424 61 g-index
63 all docs	63 docs citations	63 times ranked	4967 citing authors

#	Article	IF	Citations
1	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naÃ¯ve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. European Urology Oncology, 2022, 5, 544-552.	5.4	16
2	Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. European Urology, 2022, 82, 156-160.	1.9	43
3	Positive predictive value and correct detection rate of ¹⁸F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. Journal of Nuclear Medicine, 2021, 62, jnumed.120.255661.	5.0	5
4	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 501-508.	6.4	30
5	Prostate-specific Membrane Antigen Positron Emission Tomographyâ€“detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	3.1	34
6	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	6.4	188
7	Detection Efficacy of ¹⁸Fâ€rhPSMAâ€7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment. Journal of Nuclear Medicine, 2021, 62, 1719-1726.	5.0	14
8	Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. Journal of Nuclear Medicine, 2021, 62, 1440-1446.	5.0	37
9	Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncology, 2021, 7, 1635.	7.1	138
10	Matched-Pair Comparison of ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine, 2020, 61, 51-57.	5.0	161
11	Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. Journal of Nuclear Medicine, 2020, 61, 189-193.	5.0	19
12	Prostate-Specific Membrane Antigenâ€“Guided Surgery. Journal of Nuclear Medicine, 2020, 61, 6-12.	5.0	31
13	Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 9-15.	6.4	67
14	¹⁸F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2020, 61, 696-701.	5.0	67
15	Impact of ⁶⁸Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. Journal of Nuclear Medicine, 2020, 61, 1793-1799.	5.0	74
16	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	6.4	13
17	Impact of ⁶⁸Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. Journal of Nuclear Medicine, 2020, 61, 1153-1160.	5.0	94
18	Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomyâ€”validation of a prediction model. EJNMMI Research, 2020, 10, 6.	2.5	5

#	Article	IF	Citations
19	Detection Efficacy of ¹⁸F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2019, 60, 362-368.	5.0	238
20	Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology, 2019, 5, 856.	7.1	493
21	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. European Urology, 2019, 76, 517-523.	1.9	81
22	Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 156-157.	5.0	7
23	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. Nature Reviews Urology, 2019, 16, 159-171.	3.8	62
24	Practice changing for prostate cancer: a vision of the future. Nature Reviews Urology, 2019, 16, 71-72.	3.8	6
25	99mTechnetium-based Prostate-specific Membrane Antigenâ€“radioguided Surgery in Recurrent Prostate Cancer. European Urology, 2019, 75, 659-666.	1.9	195
26	Potential Impact of ⁶⁸Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1714-1721.	5.0	81
27	Efficacy, Predictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigenâ€“ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. European Urology, 2018, 73, 656-661.	1.9	129
28	Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. Journal of Nuclear Medicine, 2018, 59, 789-794.	5.0	68
29	Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1392-1397.	5.0	21
30	A New Type of Prostate Cancer Imaging: Will 64CuCl2 PET/CT Flourish or Vanish?. Journal of Nuclear Medicine, 2018, 59, 442-443.	5.0	5
31	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. Journal of Nuclear Medicine, 2018, 59, 469-478.	5.0	372
32	⁶⁸Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Journal of Nuclear Medicine, 2018, 59, 230-237.	5.0	226
33	Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy. Clinical Genitourinary Cancer, 2018, 16, 245-247.	1.9	8
34	Positronâ€emission tomography imaging in urological oncology: Current aspects and developments. International Journal of Urology, 2018, 25, 912-921.	1.0	10
35	The Impact of Somatostatin Receptorâ€“Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. Journal of Nuclear Medicine, 2017, 58, 756-761.	5.0	158
36	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1014-1024.	6.4	589

#	Article	IF	Citations
37	⁶⁸Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. Journal of Nuclear Medicine, 2017, 58, 1617-1623.	5.0	111
38	Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?. Journal of Nuclear Medicine, 2017, 58, 1186-1187.	5.0	4
39	Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. Journal of Nuclear Medicine, 2017, 58, 1793-1796.	5.0	24
40	Establishing ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1786-1792.	5.0	35
41	⁶⁸Gaâ€PSMAâ€PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate, 2017, 77, 920-927.	2.3	89
42	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 67S-76S.	5.0	163
43	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2117-2136.	6.4	234
44	PSMA ligands in prostate cancer â€“ Probe optimization and theranostic applications. Methods, 2017, 130, 42-50.	3.8	43
45	¹⁷⁷Lu-PSMA Radioligand Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1196-1200.	5.0	159
46	Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Research, 2016, 6, 78.	2.5	78
47	Value of ⁶⁸Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Journal of Nuclear Medicine, 2016, 57, 1713-1719.	5.0	213
48	Long-term effects on subscapularis integrity and function following arthroscopic shoulder stabilization with a low anteroinferior (5:30 oâ€™clock) portal. Knee Surgery, Sports Traumatology, Arthroscopy, 2016, 24, 422-429.	4.2	6
49	Non-invasive Differentiation of Kidney Stone Types using X-ray Dark-Field Radiography. Scientific Reports, 2015, 5, 9527.	3.3	37
50	Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine, 2015, 56, 668-674.	5.0	907
51	Evaluation of T 1Ï•as a potential MR biomarker for liver cirrhosis: Comparison of healthy control subjects and patients with liver cirrhosis. European Journal of Radiology, 2014, 83, 900-904.	2.6	45
52	Performance of Whole-Body Integrated ¹⁸F-FDG PET/MR in Comparison to PET/CT for Evaluation of Malignant Bone Lesions. Journal of Nuclear Medicine, 2014, 55, 191-197.	5.0	134
53	Systematic Comparison of the Performance of Integrated Whole-Body PET/MR Imaging to Conventional PET/CT for ¹⁸F-FDG Brain Imaging in Patients Examined for Suspected Dementia. Journal of Nuclear Medicine, 2014, 55, 923-931.	5.0	46
54	Current Staging Procedures in Urinary Bladder Cancer. Diagnostics, 2013, 3, 315-324.	2.6	9

#	Article	IF	Citations
55	Detection and classification of focal liver lesions in patients with colorectal cancer: Retrospective comparison of diffusion-weighted MR imaging and multi-slice CT. European Journal of Radiology, 2012, 81, 683-691.	2.6	45
56	Simulation of a MRâ€“PET protocol for staging of head-and-neck cancer including Dixon MR for attenuation correction. European Journal of Radiology, 2012, 81, 2658-2665.	2.6	31
57	Targeted dual-energy single-source CT for characterisation of urinary calculi: experimental and clinical experience. European Radiology, 2012, 22, 251-258.	4.5	53
58	Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1691-1701.	6.4	161
59	Wholeâ€body MRI including diffusionâ€weighted imaging (DWI) for patients with recurring prostate cancer: Technical feasibility and assessment of lesion conspicuity in DWI. Journal of Magnetic Resonance Imaging, 2011, 33, 1160-1170.	3.4	83
60	Preliminary Results for Characterization of Pelvic Lymph Nodes in Patients With Prostate Cancer by Diffusion-Weighted MR-Imaging. Investigative Radiology, 2010, 45, 15-23.	6.2	143